Conclusions
ONJ is a rare but a very serious complication in relation to treatment with bisphosphonates. To decrease the incidence of ONJ, a maxillofacial examination could be performed in all patients before treatment with bisphosphonates. Abbreviations: BRONJ, bisphosphonate-related osteonecrosis of the jaw; IV, intravenous. *Exposed bone in maxillofacial region without resolution within 8-12 weeks in persons treated with bisphosphonate who have not undergone radiotherapy to jaws. †Regardless of disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone;extraction of symptomatic teeth within exposed, necrotic bone should be considered because it is unlikely that extraction will exacerbate established necrotic process. ‡Discontinuation of IV bisphosphonates has shown no short-term benefit. However, if systemic conditions permit,long-term discontinuation might be beneficial in stabilizing established sites of BRONJ, reducing risk of new site development,and reducing clinical symptoms. Risks and benefits of continuing bisphosphonate therapy should be made only by treating oncologist in consultation with oral and maxillofacial surgeon and patient. §Discontinuation of oral bisphosphonate therapy in patients with BRONJ has been associated with gradual improvement in clinical disease. Discontinuation of oral bisphosphonates for 6-12 months may result in either spontaneous sequestration or resolution after debridement surgery. If systemic conditions permit, modification or cessation of oral bisphosphonate therapy should be done in consultation with treating physician and patient.
